Thus, the anti-tumoral action of metformin is not precluded in PTEN+/− [23, 24], HER2 [25, 26], and APCmin/+ [27] mouse tumor models, in which insulin-related markers are not significantly attenuated by treatment with metformin. Here, ERBB2 is linked to neoplasm.